266 related articles for article (PubMed ID: 10603193)
1. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells.
Morgan RL; De Young BR; McGaughy VR; Niemann TH
Cancer; 1999 Dec; 87(6):390-4. PubMed ID: 10603193
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
Hyun TS; Barnes M; Tabatabai ZL
Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
[TBL] [Abstract][Full Text] [Related]
3. Utility of MOC-31 monoclonal antibody in differentiating metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cytology.
Patil B; Shivkumar V; Gangane N
Indian J Pathol Microbiol; 2018; 61(1):90-93. PubMed ID: 29567891
[TBL] [Abstract][Full Text] [Related]
4. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.
Edwards C; Oates J
J Clin Pathol; 1995 Jul; 48(7):626-30. PubMed ID: 7560168
[TBL] [Abstract][Full Text] [Related]
5. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
6. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
7. MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma.
Niemann TH; Hughes JH; De Young BR
Cancer; 1999 Oct; 87(5):295-8. PubMed ID: 10536355
[TBL] [Abstract][Full Text] [Related]
8. Use of the monoclonal antibody MOC-31 as an immunomarker for detecting metastatic adenocarcinoma in effusion cytology.
Kundu UR; Krishnamurthy S
Cancer Cytopathol; 2011 Aug; 119(4):272-8. PubMed ID: 21732548
[TBL] [Abstract][Full Text] [Related]
9. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
10. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
11. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
12. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
Bhalla R; Siddiqui MT; Mandich D; Cartun RW; Fiel-Gan MD; Nassar A; Mandavilli SR
Diagn Cytopathol; 2007 Jun; 35(6):342-7. PubMed ID: 17497664
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
Han AC; Peralta-Soler A; Knudsen KA; Wheelock MJ; Johnson KR; Salazar H
Hum Pathol; 1997 Jun; 28(6):641-5. PubMed ID: 9190996
[TBL] [Abstract][Full Text] [Related]
15. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
16. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
Delahaye M; van der Ham F; van der Kwast TH
Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
[TBL] [Abstract][Full Text] [Related]
17. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.
Chhieng DC; Yee H; Schaefer D; Cangiarella JF; Jagirdar J; Chiriboga LA; Jagirdar J; Chiriboga LA; Cohen JM
Cancer; 2000 Jun; 90(3):194-200. PubMed ID: 10896333
[TBL] [Abstract][Full Text] [Related]
18. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
20. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
